Disulfiram neuropathy

Louis H Weimer MD (

Dr. Weimer of Columbia University has received consulting fees from Roche.

)
Originally released November 2, 1999; last updated January 16, 2021; expires January 16, 2024

Overview

Disulfiram is a long-established agent for the treatment of chronic alcoholism, and there has been interest in this agent to combat chronic cocaine abuse. The author discusses current knowledge of the associated peripheral neuropathy that primarily affects large fiber sensory and motor fibers. In some cases, the neuropathy can be confused with alcoholic polyneuropathy or thiamine deficiency neuropathy in alcoholics, but the clinical features differ to some degree. Recognition of the phenomenon is critical prior to significant nerve injury.

Key points

 

• Disulfiram produces a dose- and length-dependent axonal sensorimotor neuropathy.

 

• Disulfiram use is expanding from ethanol to cocaine dependence.

 

• Motor and large fiber sensory nerve involvement from disulfiram differs from typical chronic alcohol-induced sensory neuropathy.

Historical note and terminology

The effects of disulfiram in combination with ethanol were discovered by 2 Danish physicians investigating the agent's use as an anthelminthic after they had accidentally induced a disulfiram-alcohol reaction in themselves. The drug was subsequently approved by the FDA in 1951 for the treatment of alcoholism and remains in use despite other effective agents, such as naltrexone and acamprosate (Grover and Basu 2004). Disulfiram blocks the oxidation of alcohol at the acetaldehyde stage. During alcohol metabolism following disulfiram intake, the concentration of acetaldehyde occurring in the blood may be 5 to 10 times higher than that found during metabolism of the same amount of alcohol alone. This accumulation of acetaldehyde produces sensitivity to alcohol, resulting in a highly unpleasant disulfiram-alcohol reaction when the patient, under treatment, ingests relatively small amounts of ethanol. Disulfiram is still in use as a deterrent to drinking ethanol in the United States, Europe, and other places around the world. The drug is court mandated in some situations, but evidence suggests that compliance is poor in this setting.

The drug has been studied for the deterrence of cocaine addiction (Carroll et al 2004; Sofuoglu and Kosten 2005). Disulfiram has demonstrated efficacy in numerous randomized clinical trials for the treatment of cocaine dependence, but it is rarely used in clinical settings because of safety concerns (Malcolm et al 2008; Oliveto et al 2011). A Cochrane review, however, concluded that the evidence supporting disulfiram use in cocaine abuse was low and that large trials were needed (Pani et al 2010). A randomized trial of disulfiram also found a limited benefit supplementing buprenorphine treatment (Schottenfeld et al 2014). However, neuropathy appears to be much less common in this population. A single nucleotide polymorphism (SNP; C-1021T) in the dopamine beta-hydroxylase gene is relevant to paranoia associated with disulfiram pharmacotherapy for cocaine addiction (Haile et al 2009). Some have also suggested that disulfiram may be useful for pathologic gambling, but studies have not been performed (Mutschler et al 2010). Disulfiram also shows some promise as an antifungal agent (Shukla et al 2004).

Disulfiram combined with copper is an emerging antitumor therapy in a variety of settings, including solid and hematological cancers (Chiba et al 2014; Paranjpe et al 2014; Ekinci et al 2019). The drug may act as a tumor sensitizer to other therapies, including conventional chemotherapy and immune modulators. It appears to affect the PD-L1 pathway (Zhou et al 2019). There is evidence of inhibition of the cytokine and macrophage signal regulator FROUNT that may augment checkpoint inhibitor therapies (Terashima et al 2020). Most reported studies are in vitro models but human trials are ongoing. Expansion of usage might initiate an increase in neuropathy cases.

Disulfiram additionally shows strong activity against Lyme disease spirochetes in a high throughput search. A retrospective open label review of “high-dose” (≥ 4 mg/kg/day) and “low-dose” (< 4 mg/kg/day) treatment was performed in 71 chronic Lyme disease patients; 67 completed the trial (Gao et al 2020). Gao and colleagues reported that 92% had symptomatic improvement. Toxicity in the high-dose group included fatigue (66.7%), psychiatric symptoms (48.5%), peripheral neuropathy (27.3%), and mild-to-moderate elevation of liver enzymes (15.2%). Patients with preexisting neuropathy were preferentially in the low-dose group. They reported all but 1 patient had neuropathy symptoms resolve but no neurologic or electrodiagnostic studies were mentioned (Gao et al 2020). They suggested randomized trials are warranted.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.

Find out how you can join MedLink Neurology